Eli Lilly's Oral Obesity Pill Shows Promise as an Effective Alternative to Injectable GLP-1s
TL;DR Summary
Eli Lilly's new oral obesity pill, orforglipron, shows comparable effectiveness to injectable GLP-1 drugs like Ozempic in weight loss and blood sugar reduction, with potential advantages in cost, convenience, and accessibility, and is seeking regulatory approval.
- Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s wired.com
- Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine Eli Lilly
- Lilly expects orforglipron obesity results in third quarter Reuters
- Lilly Obesity Pill to Rival Shots Holds Up to Scrutiny in Trial Bloomberg.com
- Eli Lilly looks beyond its blockbuster obesity drugs with another smart deal CNBC
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
3 min
vs 4 min read
Condensed
94%
619 → 36 words
Want the full story? Read the original article
Read on wired.com